MannKind (MNKD) 10-Q 11 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	4-May-15
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	MNKD
Entity Registrant Name	MANNKIND CORP
Entity Central Index Key	899460
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		409,576,765

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$120,844	$120,841
Receivables from collaboration	4,282	50,436
Inventory	16,789	9,670
Prepaid expenses and other current assets	16,375	20,206
Total current assets	158,290	201,153
Property and equipment - net	193,454	192,127
Deferred products costs from collaboration	6,251
Other assets	2,027	1,159
Total	360,022	394,439
Current liabilities:
Accounts payable	3,302	7,394
Accrued expenses and other current liabilities	12,381	26,206
Facility financing obligation	73,368	72,995
Senior convertible notes	99,593	99,355
Deferred product sales from collaboration	7,050
Deferred payments from collaboration	185,059	197,403
Total current liabilities	380,753	403,353
Note payable to principal stockholder	49,521	49,521
Other liabilities	26,779	15,335
Total liabilities	457,053	468,209
Commitments and contingencies
Stockholders' equity (deficit):
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at March 31, 2015 and December 31, 2014
Common stock, $0.01 par value - 550,000,000 shares authorized at March 31, 2015 and December 31, 2014; 409,116,346 and 406,059,089 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	4,090	4,061
Additional paid-in capital	2,424,347	2,416,967
Accumulated other comprehensive loss	-21	-14
Accumulated deficit	-2,525,447	-2,494,784
Total stockholders' (deficit)	-97,031	-73,770
Total	$360,022	$394,439

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Undesignated preferred stock, par value	$0.01	$0.01
Undesignated preferred stock, shares authorized	10,000,000	10,000,000
Undesignated preferred stock, shares issued	0	0
Undesignated preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	550,000,000	550,000,000
Common stock, shares issued	409,116,346	406,059,089
Common stock, shares outstanding	409,116,346	406,059,089

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenue	$0	$0
Operating expenses:
Research and development	9,377	26,182
General and administrative	10,479	15,229
Product manufacturing	1,882
Total operating expenses	21,738	41,411
Loss from operations	-21,738	-41,411
Other income (expense)	1,413	-5,890
Interest expense on note payable to principal stockholder	-714	-714
Interest expense on notes	-9,622	-4,042
Interest income	3	1
Loss before benefit for income taxes	-30,658	-52,056
Income tax benefit	0	0
Net loss	($30,658)	($52,056)
Net loss per share - basic and diluted	($0.08)	($0.14)
Shares used to compute basic and diluted net loss per share	398,916	368,784

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net loss	($30,658)	($52,056)
Other comprehensive loss:
Cumulative translation (loss) gain	-7
Unrealized gain (loss) on investments:
Unrealized holding gain (loss) during the period	0	0
Less: reclassification adjustment for gains (losses) included in net loss	0	0
Net unrealized (loss) gain on investments	0	0
Other comprehensive loss	-7
Comprehensive loss	($30,665)	($52,056)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	($30,658)	($52,056)
Adjustments to reconcile net loss to net cash provided by (used) in operating activities:
Depreciation and accretion	2,988	9,394
Stock-based compensation expense	2,003	10,937
Other, net	-7
Changes in assets and liabilities:
Inventory	-7,119
Receivables from Collaboration	46,154
Prepaid expenses and other current assets	3,831	1,845
Deferred product costs from collaboration	-6,251
Other assets	-872	-82
Accounts payable	-4,182	-1,038
Accrued expenses and other current liabilities	-10,660	-6,704
Deferred product sales from collaboration	7,050
Other liabilities	743	714
Net cash provided by (used in) operating activities	3,020	-36,990
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	-4,203	-1,409
Net cash used in investing activities	-4,203	-1,409
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock and warrants, net of issuance costs	6,168	3,401
Milestone payment	-4,220
Payment of employment taxes related to vested restricted stock units	-762	-33
Net cash provided by financing activities	1,186	3,368
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	3	-35,031
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	120,841	70,790
CASH AND CASH EQUIVALENTS, END OF PERIOD	120,844	35,759
SUPPLEMENTAL CASH FLOWS DISCLOSURES:
Interest paid in cash, net of amounts capitalized	4,749	4,678
Issuance of common stock for notes receivable		86,000
Non-cash construction in progress and property and equipment	1,094	1,700
Tranche B Commitment Asset		$2,921

Description_of_business_and_ba

Description of business and basis of presentation	3 Months Ended
	Mar. 31, 2015
Description of business and basis of presentation	1. Description of business and basis of presentation
	The accompanying unaudited condensed consolidated financial statements of MannKind Corporation and its subsidiaries (“MannKind,” the “Company,” “we” or “us”), have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2014 filed with the SEC on March 2, 2015 (the “Annual Report”).
	In the opinion of management, all adjustments, consisting only of normal, recurring adjustments, considered necessary for a fair presentation of the results of these interim periods have been included. The results of operations for the three months ended March 31, 2015 may not be indicative of the results that may be expected for the full year.
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates or assumptions. The more significant estimates reflected in these accompanying financial statements involve assessing long-lived assets and deferred product costs for impairment, accrued expenses, valuation of stock-based compensation and the determination of the provision for income taxes and corresponding deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.
	Business — MannKind is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. Our only approved product, AFREZZA (insulin human [rDNA origin]) inhalation powder, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration (the “FDA”) on June 27, 2014 to improve glycemic control in adult patients with diabetes. In August 2014, we entered into a license and collaboration agreement (the “Sanofi License Agreement”) with Sanofi-Aventis Deutschland GmbH (which subsequently assigned its rights and obligations under the agreement to Sanofi-Aventis U.S. LLC (“Sanofi”)), pursuant to which Sanofi conducts all sales and marketing activities related to AFREZZA (see Note 7 – Collaboration arrangement). AFREZZA became available by prescription in United States retail pharmacies in February 2015.
	Basis of Presentation — The Company’s primary activities since incorporation have been establishing its facilities, recruiting personnel, conducting research and development, business development, business and financial planning, and raising capital. It is costly to develop therapeutic products and conduct associated clinical studies. As of March 31, 2015, the Company had an accumulated deficit of $2.5 billion and a stockholders’ deficit of $97.0 million. Historically the Company has reported negative cash flow from operations other than for the nine months ended September 30, 2014 and for the three months ended March 31, 2015, as a result of receipt of the upfront payment and milestone payments under the Sanofi License Agreement.
	At March 31, 2015, the Company’s capital resources consisted of cash and cash equivalents of $120.8 million. The Company expects to continue to incur significant expenditures to support commercial manufacturing of AFREZZA and the development of other product candidates. In addition, the Company had $232.5 million principal amount of outstanding debt as of March 31, 2015, including $100.0 million principal amount of outstanding 5.75% Senior Convertible Notes due 2015 (the “2015 notes”), which have a maturity date of August 15, 2015. See Note 5 – Related-party arrangements, Note 6 – Senior convertible notes, Note 7 – Collaboration arrangement—Sanofi Loan Facility, and Note 14 – Facility Agreement. In addition, the Company’s facility agreement (the “Facility Agreement”) with Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, “Deerfield”) (see Note 14 – Facility Agreement) contains a financial covenant that requires the Company’s cash and cash equivalents, which include available borrowings under the Company’s loan arrangement (the “Loan Arrangement”) with The Mann Group LLC (“The Mann Group”), on the last day of each fiscal quarter to not be less than $25.0 million. Should the holders of the notes not elect to convert such notes into the Company’s common stock prior to their due date, the Company intends to refinance the 2015 notes or raise additional funds to settle the 2015 notes. The Company cannot be certain that it will achieve its projected cashflows or be able to refinance the 2015 notes, which raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.
	On August 11, 2014, the Company executed a license and collaboration agreement (the “Sanofi License Agreement”) and a supply agreement (the “Sanofi Supply Agreement”) with Sanofi-Aventis Deutschland GmbH (which subsequently assigned its rights and obligations under the agreement to Sanofi-Aventis U.S. LLC (“Sanofi”)), pursuant to which Sanofi is responsible for global commercial, regulatory and development activities for AFREZZA. The Sanofi License Agreement became effective on September 23, 2014. The Company manufactures AFREZZA at its manufacturing facility in Danbury, Connecticut to supply Sanofi’s demand for the product. In addition, the Company and Sanofi are planning to collaborate to expand manufacturing capacity to meet global demand as necessary.
	Under the Sanofi License Agreement, Sanofi paid us an up-front cash payment of $150.0 million in the third quarter of 2014, and $50.0 million in milestone payments in the first quarter of 2015. The foregoing milestone payments were earned as of December 31, 2014. We are also eligible to receive up to $725.0 million in additional milestone payments under the Sanofi License Agreement if certain development, regulatory and sales milestones are achieved Worldwide profits and losses, which are determined based on the difference between the net sales of AFREZZA and the costs and expenses incurred by us and Sanofi that are specifically attributable or related to the development, regulatory filings, manufacturing, or commercialization of AFREZZA, will be shared 65% by Sanofi and 35% by us. In connection with the Sanofi License Agreement, an affiliate of Sanofi provided us with a secured loan facility (the “Sanofi Loan Facility”) of up to $175.0 million to fund our share of net losses under the Sanofi License Agreement.
	Additional funding sources that are, or in certain circumstances may be available to the Company, include approximately $30.1 million principal amount of available borrowings under its Loan Arrangement (see Note 5 – Related-party arrangements), potential proceeds from the exercise of warrants issued in its February 2012 public offering of approximately $14.9 million, and the Company’s at-the-market issuance sales agreements which allow the Company to sell up to $50.0 million in common stock provided no sales may be made except pursuant to an effective registration statement. The registration statement under which the shares that may be sold pursuant to the at-the-market issuance sales agreements are registered will expire in August 2015. The Company cannot provide assurances that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company may need to raise additional capital, whether through a sale of equity or debt securities, a strategic business collaboration with a pharmaceutical company, the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to continue the development and commercialization of AFREZZA and other product candidates and to support its other ongoing activities. However, the Company cannot provide assurances that such additional capital will be available on acceptable terms or at all.
	Fair Value of Financial Instruments — The carrying amounts reported in the accompanying financial statements for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their relatively short maturities. The fair value of the cash equivalents, note payable to related party, senior convertible notes, and the Facility Agreement are discussed in Note 9 – Fair Value of Financial Instruments.
	Deferred product costs from collaboration — Deferred product costs represent the costs of product manufactured and shipped to Sanofi, not to exceed the amount of deferred product sales related to the collaboration, for which recognition of revenue has been deferred. Given that the costs of inventory delivered to a customer, but for which revenue may not yet be recognized, meet both the definition and characteristics of an “Asset” and the Company believes that it is probable that the amount of future revenue will exceed the amount of deferred costs (i.e., the asset would be realizable through the recognition of probable future income), the Company has elected to account for the deferred costs related to the product sold to Sanofi as an asset and carry forward to future periods until the related revenue is recognized.
	Recently Issued Accounting Standards — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date.
	In May 2014, a new standard was issued related to revenue recognition, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The guidance requires a company to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration it expects to be entitled to receive in exchange for those goods or services. The standard is effective beginning the first quarter of the Company’s 2018 fiscal year (with early adoption not permitted) and may be adopted either by restating all years presented in the Company’s financial statements or by recording the impact of adoption as an adjustment to retained earnings at the beginning of fiscal 2018 The Company is assessing the potential impact of the new standard on its consolidated statements of financial position and results of operations and comprehensive income (loss) and has not yet selected a transition method.
	In August 2014, the FASB issued ASU 2014-15, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is “substantial doubt about the entity’s ability to continue as a going concern.” The ASU is effective for annual periods ending after December 15, 2016, and interim periods thereafter; early adoption is permitted. The Company is evaluating the impact the adoption of ASU 2014-15 will have on its consolidated financial statements.
	In April 2015, the FASB issued ASU 2015 03, “Simplifying the Presentation of Debt Issuance Costs.” The guidance requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt, consistent with the presentation of a debt discount. The guidance is effective for annual reporting periods beginning after December 15, 2015 and interim periods thereafter. Early adoption is permitted. The Company does not believe the adoption of the new standard will have a material impact on its consolidated financial statements and disclosures.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2015
Inventories	2. Inventories
	Inventories consist of the following (in thousands):
		March 31,		December 31,
		2015		2014
	Raw materials	$	10,075	$	4,856
	Work-in-process		5,550		4,719
	Finished goods		1,164		95
	Total inventories	$	16,789	$	9,670

Property_and_equipment

Property and equipment	3 Months Ended
	Mar. 31, 2015
Property and equipment	3. Property and equipment
	Property and equipment — net consist of the following (dollar amounts in thousands):
		Estimated		March 31,			December 31,
		Useful		2015			2014
		Life
		(Years)
	Land		—	$	5,273		$	5,273
	Buildings		39-40		54,948			54,948
	Building improvements		May-40		114,131			114,131
	Machinery and equipment		15-Mar		82,120			80,919
	Furniture, fixtures and office equipment		10-May		5,015			5,015
	Computer equipment and software		3		10,499			10,465
	Leasehold improvements		4		17			17
	Construction in progress				41,997			39,580
					314,000			310,348
	Less accumulated depreciation and amortization				(120,546	)		(118,221	)
	Property and equipment — net			$	193,454		$	192,127
	Leasehold improvements are amortized over four years which is the shorter of the term of the lease or the service lives of the improvements.
	Depreciation and amortization expense related to property and equipment for the three months ended March 31, 2015 and 2014 was $2.3 million and $2.5 million, respectively.

Accrued_expenses_and_other_cur

Accrued expenses and other current liabilities	3 Months Ended
	Mar. 31, 2015
Accrued expenses and other current liabilities	4. Accrued expenses and other current liabilities
	Accrued expenses and other current liabilities are comprised of the following (in thousands):
		March 31,		December 31,
		2015		2014
	Salary and related expenses	$	7,386	$	14,928
	Accrued interest		1,022		2,396
	Construction in progress		579		1,343
	Other		3,394		7,539
	Accrued expenses and other current liabilities	$	12,381	$	26,206

Relatedparty_arrangements

Related-party arrangements	3 Months Ended
	Mar. 31, 2015
Related-party arrangements	5. Related-party arrangements
	In October 2007, the Company entered into a $350.0 million loan arrangement with its principal stockholder. The Loan Arrangement has been amended from time to time. On October 31, 2013, the promissory note underlying the Loan Arrangement was amended to, among other things, extend the maturity date of the loan to January 5, 2020, extend the date through which the Company can borrow under the Loan Arrangement to December 31, 2019, increase the aggregate borrowing amount under the Loan Arrangement from $350.0 million to $370.0 million and provide that repayments or cancellations of principal under the Loan Arrangement will not be available for reborrowing.
	As of March 31, 2015, the total principal amount outstanding under the Loan Arrangement was $49.5 million, and the amount available for future borrowings was $30.1 million. Interest, at a fixed rate of 5.84%, is due and payable quarterly in arrears on the first day of each calendar quarter for the preceding quarter, or at such other time as the Company and The Mann Group mutually agree. All or any portion of accrued and unpaid interest that becomes due and payable may be paid-in-kind and capitalized as additional borrowings at any time and would be classified as non-current upon mutual agreement of both parties. As of March 31, 2015, the Company had accrued $4.2 million of interest in other liabilities related to the Loan Arrangement. The Mann Group can require the Company to prepay up to $200.0 million in advances that have been outstanding for at least 12 months (less approximately $105.0 million aggregate principal amount that has been cancelled in connection with two common stock purchase agreements). If The Mann Group exercises this right, the Company will have 90 days after The Mann Group provides written notice (or the number of days to maturity of the note if less than 90 days) to prepay such advances. However, pursuant to a letter agreement entered into in August 2010, The Mann Group has agreed to not require the Company to prepay amounts outstanding under the amended and restated promissory note if the prepayment would require the Company to use its working capital resources. The Mann Group entered into a subordination agreement with Deerfield pursuant to which The Mann Group agreed with Deerfield not to demand or accept any payment under the Loan Arrangement until the Company’s payment obligations to Deerfield under the Facility Agreement have been satisfied in full. Subject to the foregoing, in the event of a default under the Loan Arrangement, all unpaid principal and interest either becomes immediately due and payable or may be accelerated at The Mann Group’s option, and the interest rate will increase to the one-year LIBOR calculated on the date of the initial advance or in effect on the date of default, whichever is greater, plus 5% per annum. All borrowings under the Loan Arrangement are unsecured. The Loan Arrangement contains no financial covenants.
	During the three months ended March 31, 2015, there were no additional borrowings under or amendments to the Loan Arrangement.

Senior_convertible_notes

Senior convertible notes	3 Months Ended
	Mar. 31, 2015
Senior convertible notes	6. Senior convertible notes
	Senior convertible notes consist of the following (in thousands):
		March 31,			December 31,
		2015			2014
	2015 notes
	Principal amount	$	100,000		$	100,000
	Unaccreted debt issuance expense		(407	)		(645	)
	Net carrying amount	$	99,593		$	99,355
	On August 18, 2010, the Company completed a Rule 144A offering of $100.0 million aggregate principal amount of 2015 notes. The 2015 notes are governed by the terms of an indenture dated as of August 24, 2010 (the “2015 Note Indenture”). The 2015 notes bear interest at the rate of 5.75% per year on the principal amount, payable in cash semi-annually in arrears on February 15 and August 15 of each year, beginning February 15, 2011. In connection with the 2015 notes, the Company had accrued interest of $1.0 million and $2.4 million as of March 31, 2015 and December 31, 2014, respectively. The 2015 notes are general, unsecured, senior obligations of the Company and effectively rank junior in right of payment to all of the Company’s secured debt, to the extent of the value of the assets securing such debt, and to the debt and all other liabilities of the Company’s subsidiaries. The maturity date of the 2015 notes is August 15, 2015 and payment is due in full on that date for unconverted securities. Holders of the 2015 notes may convert, at any time prior to the close of business on the business day immediately preceding the stated maturity date, any outstanding principal into shares of the Company’s common stock at an initial conversion rate of 147.0859 shares per $1,000 principal amount, which is equal to a conversion price of approximately $6.80 per share, subject to adjustment. Except in certain circumstances, if the Company undergoes a fundamental change: (1) the Company will pay a make-whole premium on the 2015 notes converted in connection with a fundamental change by increasing the conversion rate on such 2015 notes, which amount, if any, will be based on the Company’s common stock price and the effective date of the fundamental change, and (2) each holder of 2015 notes will have the option to require the Company to repurchase all or any portion of such holder’s 2015 notes at a repurchase price of 100% of the principal amount of the 2015 notes to be repurchased plus accrued and unpaid interest, if any. The Company may elect to redeem some or all of the 2015 notes if the closing stock price has equaled 150% of the conversion price for at least 20 of the 30 consecutive trading days ending on the trading day before the Company’s redemption notice. The redemption price will equal 100% of the principal amount of the 2015 notes to be redeemed, plus accrued and unpaid interest, if any, up to, but excluding, the redemption date, plus a make-whole payment equal to the sum of the present values of the remaining scheduled interest payments through and including August 15, 2015 (other than interest accrued up to, but excluding, the redemption date). The Company will be obligated to make the make-whole payment on all of the 2015 notes called for redemption and converted during the period from the date the Company mailed the notice of redemption to and including the redemption date. The Company may elect to make the make-whole payment in cash or shares of its common stock, subject to certain limitations. Under the terms of the 2015 Note Indenture, the conversion option can be net-share settled and the maximum number of shares that could be required to be delivered under the contract, including the make-whole shares, is fixed and less than the number of authorized and unissued shares less the maximum number of shares that could be required to be delivered during the contract period under existing commitments. Applying the Company’s sequencing policy, the Company performed an analysis at the time of the offering of the 2015 notes and each reporting date since and has concluded that the number of available authorized shares at the time of the offering and each subsequent reporting date was sufficient to deliver the number of shares that could be required to be delivered during the contract period under existing commitments.
	The Company incurred approximately $4.2 million in issuance costs which are recorded as an offset to the 2015 notes in the accompanying condensed consolidated balance sheets. These costs are being accreted to interest expense using the effective interest method over the term of the 2015 notes.
	The 2015 notes provide that upon an acceleration of certain indebtedness, including the 9.75% Senior Convertible Notes due 2019 (the “2019 notes”) and the 8.75% Senior Convertible Notes due 2019 (the “Tranche B notes”) issued to Deerfield pursuant to the Facility Agreement (see Note 14 – Facility Agreement), the holders may elect to accelerate the Company’s repayment obligations under the notes if such acceleration is not cured, waived, rescinded or annulled. There can be no assurance that the holders would not choose to exercise these rights in the event such events were to occur.
	Accretion of debt issuance expense in connection with the 2015 notes during the three months ended March 31, 2015 and 2014 was $238,000 and $223,000, respectively.

Collaboration_arrangement

Collaboration arrangement	3 Months Ended
	Mar. 31, 2015
Collaboration arrangement	7. Collaboration arrangement
	Sanofi License Agreement and Sanofi Supply Agreement
	On August 11, 2014, the Company and Sanofi entered into the Sanofi License Agreement, which became effective on September 23, 2014. Under the terms of the Sanofi License Agreement, the Company granted to Sanofi exclusive, worldwide licenses to certain of the Company’s patents, trademarks and know-how for the development and commercialization of AFREZZA. Under the terms of the Sanofi License Agreement, Sanofi has the exclusive right and responsibility to develop AFREZZA worldwide, subject to certain development activities that will be performed by the Company. Sanofi will also be obligated to use commercially reasonable efforts to file for, obtain and maintain marketing approvals for AFREZZA in certain major markets and countries. In addition, Sanofi will have exclusive, worldwide rights to commercialize AFREZZA and will be obligated to use commercially reasonable efforts to market, promote and commercialize AFREZZA in all countries in the world where regulatory approval for AFREZZA has been received. Under the Sanofi License Agreement, Sanofi paid the Company an up-front cash payment of $150.0 million in the third quarter of 2014 and a subsequent payment of $50.0 million in the first quarter of 2015 for the achievement of two manufacturing milestones as of December 31, 2014. If certain development, regulatory and sales milestones are achieved, the Company will also be eligible to receive up to $725.0 million in additional milestone payments, of which $25.0 million relates to a development milestone event, $50.0 million relates to the filing and completion of regulatory approvals and $650.0 million relates to the achievement of certain product sales milestones. In addition, worldwide profits and losses, which are determined based on the difference between the net sales of AFREZZA and the costs and expenses incurred by the Company and Sanofi that are specifically attributable or related to the development, improvement, regulatory filings, manufacturing, and commercialization of AFREZZA will be shared 65% by Sanofi and 35% by the Company. In accordance with the terms of the Sanofi License Agreement, profit and loss sharing commenced in the fourth quarter of 2014.
	Pursuant to the terms of the Sanofi Supply Agreement, the Company will be the exclusive manufacturer and supplier of AFREZZA until the specified conditions are met, upon which a portion of the manufacturing activities may be assumed by Sanofi.
	The Company analyzed the agreements entered into with Sanofi under the provisions of ASC 605, Revenue Recognition, to determine whether the consideration, or a portion thereof, could be recognized as revenue. ASC 605 provides that revenue is recognized when there is persuasive evidence that an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collection is reasonably assured. In addition, revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer. When deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price of each deliverable and the appropriate revenue recognition principles are applied to each unit.
	The assessment of multiple element arrangements requires judgment in order to determine the appropriate units of accounting and the points in time that, or periods over which, revenue should be recognized. Under the terms of the Sanofi License Agreement, Sanofi Supply Agreement and the Sanofi Loan Facility the Company determined that the arrangement contained significant deliverables including (i) licenses to develop and commercialize AFREZZA and to use the Company’s trademarks, (ii) development activities, and (iii) manufacture and supply services for AFREZZA. Due to the proprietary nature of the manufacturing services being provided by the Company, the Company determined that all of the significant deliverables should be combined into a single unit of accounting. The Company believes that the manufacturing services are proprietary due to the fact that since the late 1990’s, the Company has developed proprietary knowledge and patented equipment and tools that are used in the manufacturing process of AFREZZA. Due to the complexities of particle formulation and the specialized knowledge and equipment needed to handle the AFREZZA powder, neither Sanofi nor any third-party contract manufacturing organization currently possesses the capability of manufacturing AFREZZA.
	In order for revenue to be recognized, the seller’s price to the buyer must be fixed and determinable. Given that as of March 31, 2015, the Company did not have the ability to estimate the amount of costs that would potentially be incurred under the loss share provision related to the Sanofi License Agreement and the Sanofi Supply Agreement, the Company believes this requirement for revenue recognition has not been met.
	As such, the Company did not recognize any revenue pursuant to the Sanofi License Agreement or the Sanofi Supply Agreement for the three months ended March 31, 2015. The Company has recorded the $150.0 million up-front payment and $50.0 million from milestone payments as deferred payments from collaboration. In addition, as of March 31, 2015 the Company has recorded $7.1 million in AFREZZA product shipments to Sanofi recorded as deferred product sales from collaboration and recorded $6.3 million as deferred product costs from collaboration. Deferred product costs represent the costs of product manufactured and shipped to Sanofi, not to exceed the amount of deferred product sales, for which recognition of revenue has been deferred. During the quarter ended March 31, 2015, the Company’s portion of the loss sharing was $12.4 million, which resulted in the reclassification from current deferred payments from collaboration to other long-term liabilities.
	Sanofi Loan Facility
	On September 23, 2014, the Company entered into the Sanofi Loan Facility, consisting of a senior secured revolving promissory note (the “Note”) and a guaranty and security agreement (the “Security Agreement”) with an affiliate of Sanofi which provides the Company with a secured loan facility of up to $175.0 million to fund the Company’s share of net losses under the Sanofi License Agreement. In the event of certain future defaults under the Sanofi Loan facility agreement for which the Company is not able to obtain waivers, the lender under the Sanofi Loan Facility may accelerate all of the Company’s repayment obligations, and take control of the Company’s pledged assets, potentially requiring the Company to renegotiate the terms of its indebtedness on terms less favorable to the Company, or to immediately cease operations.
	Advances under the Sanofi Loan Facility bear interest at a rate of 8.5% per annum and are payable in-kind and compounded quarterly and added to the outstanding principal balance under the Sanofi Loan Facility. The Company is required to make mandatory prepayments on the outstanding loans under the Sanofi Loan Facility from its share of any Profits (as defined in the Sanofi License Agreement) under the Sanofi License Agreement within 30 days of receipt of its share of any such Profits. No advances may be made under the Sanofi Loan Agreement if Deerfield has commenced enforcement proceedings in connection with an event of default under the Facility Agreement.
	The outstanding principal of all loans under the Sanofi Loan Facility, if not prepaid, will become due and payable on September 23, 2024 unless accelerated pursuant to the terms of the Sanofi Loan Facility. Additionally, if the Company sells its Valencia facility, the Company is required to prepay the loans under the Sanofi Loan Facility in an amount equal to 100% of the net cash proceeds of the sale within five business days of receipt.
	In order to fund the Company’s portion of the loss sharing during the three months ended March 31, 2015, subsequent to March 31, 2015, the Company borrowed $12.4 million under the Sanofi Loan Facility to finance the portion of the Company’s loss. As of May 11, 2015, the total amount owed to Sanofi under the Sanofi Loan Facility was $15.5 million, which includes $0.1 million in paid-in-kind interest.
	The obligations of the Company under the Sanofi Loan Facility are guaranteed by the Company’s wholly-owned subsidiary, MannKind LLC, and are secured by a first priority security interest in certain insulin inventory located in the United States and any contractual rights and obligations pursuant to which the Company purchases or has purchased such insulin, and a second priority security interest in the Company’s assets that secure the Company’s obligations under the Facility Agreement, as amended. In addition, the Company granted to Sanofi, as additional security for the obligations under the Sanofi Loan Facility, a first priority mortgage on the Company’s facility in Valencia, California.
	The Sanofi Loan Facility includes customary representations, warranties and covenants by the Company, including restrictions on its ability to incur additional indebtedness, grant certain liens and make certain changes to its organizational documents. Events of default under the Sanofi Loan Facility include: the Company’s failure to timely make payments due under the Sanofi Loan Facility; inaccuracies in the Company’s representations and warranties to the noteholder; the Company’s failure to comply with any of its covenants under any of the Sanofi Loan Facility or certain other related security agreements and documents entered into in connection with the Sanofi Loan Facility, subject to a cure period with respect to most covenants; the Company’s insolvency or the occurrence of certain bankruptcy-related events; termination by Sanofi of the Sanofi License Agreement as a result of the Company’s breach of the Sanofi License Agreement; and the failure of any material provision under any of the Sanofi Loan Facility or certain other related security agreements and documents entered into in connection with the Sanofi Loan Facility to remain in full force and effect. If one or more events of default occurs and is continuing, Sanofi may terminate its obligation to make advances under the Sanofi Loan Facility, and, if certain specified events of default (including the Company’s failure to timely make payments due under the Sanofi Loan Facility; the Company’s failure to comply with the negative covenants under the Sanofi Loan Facility limiting the Company’s ability to incur additional indebtedness or grant certain liens; the Company’s insolvency or the occurrence of certain bankruptcy-related events; termination by Sanofi of the Sanofi License Agreement as a result of the Company’s breach of the non-compete provisions of the Sanofi License Agreement; or the failure of any material provision under any of the Sanofi Loan Facility or certain other related security agreements and documents entered into in connection with the Sanofi Loan Facility to remain in full force and effect) occur and are continuing, the noteholder may accelerate all of the Company’s repayment obligations under the Sanofi Loan Facility and otherwise exercise any of its remedies as a secured creditor. There can be no assurance that the noteholder would not choose to exercise these rights in the event such events were to occur.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2015
Fair Value of Financial Instruments	8. Fair Value of Financial Instruments
	The Company applies various valuation approaches in determining the fair value of its financial assets and liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:
	Level 1— Quoted prices for identical instruments in active markets.
	Level 2— Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.
	Level 3— Significant inputs to the valuation model are unobservable.
	The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement.
	Cash and cash equivalents
	Cash equivalents consist of highly liquid investments with original or remaining maturities of 90 days or less at the time of purchase, that are readily convertible into cash. As of March 31, 2015 and December 31, 2014, the Company held $120.8 million and $120.8 million, respectively, of cash and cash equivalents, consisting primarily of money market funds of $120.5 million and $118.5 million, respectively, and the remaining in non-interest bearing checking accounts. The fair value of these money market funds was determined by using quoted prices for identical investments in an active market (Level 1 in the fair value hierarchy).
	Related-Party Arrangement
	The fair value of the note payable to our principal stockholder cannot be reasonably estimated as the Company would not be able to obtain a similar credit arrangement in the current economic environment.
	Senior convertible notes
	The following is a summary of the carrying values and estimated fair values of the 2015 notes and the facility financing obligation (i.e., the 2019 notes and Tranche B notes) (in millions):
		March 31, 2015				December 31, 2014
		Carrying		Estimated		Carrying		Estimated
		value		fair value		value		fair value
	2015 notes	$	99.6	$	102.1	$	99.4	$	102.9
	Facility financing obligation	$	73.4	$	76.1	$	73	$	75.1
	The estimated fair value of the 2015 notes was calculated based on model-derived valuations whose inputs were observable, such as the Company’s stock price, and non-observable, such as the Company’s longer-term historical volatility (Level 3 in the fair value hierarchy). As there is no current observable market for the 2015 notes, the Company determined the estimated fair value using a convertible bond valuation model within a lattice framework. The convertible bond valuation model combined expected cash outflows with market-based assumptions regarding risk-adjusted yields, stock price volatility and recent price quotes and trading information regarding Company issued debt instruments and shares of common stock into which the notes are convertible.
	Facility Agreement
	As discussed in Note 14 — Facility Agreement, in connection with the Facility Agreement, the Company issued 2019 notes and certain rights to receive payments of up to $90.0 million upon the occurrence of specified strategic and sales milestones (the “Milestone Rights”). As there is no current observable market for the 2019 notes or Tranche B notes, the Company determined the estimated fair value using a bond valuation model based on a discounted cash flow methodology. The bond valuation model combined expected cash flows associated with principal repayment and interest based on the contractual terms of the debt agreement discounted to present value using a selected market discount rate. At March 31, 2015 the market discount rate was recalculated at 12.0% for the 2019 notes and 11.0% for the Tranche B notes (Level 3 in the fair value hierarchy).
	The estimated fair value of the Milestone Rights was calculated using the income approach in which the cash flows associated with the specified contractual payments were adjusted for both the expected timing and the probability of achieving the milestones discounted to present value using a selected market discount rate (Level 3 in the fair value hierarchy). The expected timing and probability of achieving the milestones, starting in 2014, was developed with consideration given to both internal data, such as progress made to date and assessment of criteria required for achievement, and external data, such as market research studies. The discount rate (15%) was selected based on an estimation of required rate of returns for similar investment opportunities using available market data. As of March 31, 2015, the fair value of the Milestone Rights is estimated at $47.6 million.
	There were no material re-measurements to fair value during the three months ended March 31, 2015 of financial assets and liabilities that are not measured at fair value on a recurring basis. There were no transfers of assets or liabilities between the fair value measurement levels during the three months ended March 31, 2015.
	Sanofi Loan Facility
	As discussed in Note 7 — the Sanofi Loan Facility, consists of a senior secured revolving promissory note and a guaranty and security agreement with an affiliate of Sanofi which provides the Company with a secured loan facility of up to $175.0 million to fund the Company’s share of net losses under the Sanofi License Agreement. As of March 31, 2015, the Company borrowed $3.0 million under the Sanofi Loan Facility and the estimated fair value was determined to approximate the carrying value based on the consideration of the key elements of time value of money, namely the amount of time to settlement and the estimated discount rate appropriate for the liability. This analysis was performed using a discounted cash flow model in which time outstanding and discount rate were the primary variables.

Common_and_preferred_stock

Common and preferred stock	3 Months Ended
	Mar. 31, 2015
Common and preferred stock	9. Common and preferred stock
	Included in the common stock outstanding as of March 31, 2015 and December 31, 2014 are 9,000,000 shares of common stock loaned to Bank of America, N.A. under a share lending agreement in connection with the offering of $100.0 million aggregate principal amount of 2015 notes (see Note 6 — Senior convertible notes). Bank of America is obligated to return the borrowed shares (or, in certain circumstances, the cash value thereof) to the Company on or about the 45th business day following the date as of which the entire principal amount of the 2015 notes ceases to be outstanding, subject to extension or acceleration in certain circumstances or early termination at Bank of America’s option. The Company did not receive any proceeds from the sale of the borrowed shares by Bank of America, but the Company did receive a nominal lending fee of $0.01 per share from Bank of America for the use of borrowed shares.

Accounting_for_stockbased_comp

Accounting for stock-based compensation	3 Months Ended
	Mar. 31, 2015
Accounting for stock-based compensation	10. Accounting for stock-based compensation
	Total stock-based compensation expense recognized in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2015 and 2014 was $2.0 million and $5.2 million, respectively. The Company issued stock awards to employees during the three months ended March 31, 2015 with a four-year vesting schedule. The grant date fair value of the 36,300 restricted stock units and 73,600 stock options issued was $262,086 and $382,720, respectively, with a grant date fair value per share of $7.22 and $5.20, respectively.
	As of March 31, 2015, there was $9.0 million and $10.0 million of unrecognized compensation cost related to options and restricted stock units, respectively, which are expected to be recognized over the remaining weighted average vesting period of 2.6 years. The Company evaluates stock awards with performance conditions as to the probability that the performance conditions will be met and estimates the date at which the performance conditions will be met in order to properly recognize stock-based compensation expense over the requisite service period. As of March 31, 2015, there were no unrecognized expenses related to performance options and restricted stock units, for milestones not considered probable of achievement.

Net_loss_per_common_share

Net loss per common share	3 Months Ended
	Mar. 31, 2015
Net loss per common share	11. Net loss per common share
	Basic net loss per share excludes dilution for potentially dilutive securities and is computed by dividing net loss by the weighted average number of common shares outstanding during the period excluding the shares loaned to Bank of America under a share lending arrangement (see Note 9 — Common and preferred stock). As of March 31, 2015, 9,000,000 shares of the Company’s common stock, which were loaned to Bank of America pursuant to the terms of a share lending agreement as described in Note 9, were issued and are outstanding, and the holder of the borrowed shares has all the rights of a holder of the Company’s common stock. However, because the share borrower must return all borrowed shares to the Company (or, in certain circumstances, the cash value thereof), the borrowed shares are not considered outstanding for the purpose of computing and reporting basic or diluted earnings (loss) per share. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Potentially dilutive securities are excluded from the computation of diluted net loss per share for all of the periods presented in the accompanying condensed consolidated statements of operations because the reported net loss in each of these periods results in their inclusion being antidilutive. Antidilutive securities, which consist of stock options, restricted stock units, warrants, and shares that could be issued upon conversion of the senior convertible notes, that are not included in the diluted net loss per share calculation consisted of an aggregate of 45,171,595 shares and 67,791,150 shares as of March 31, 2015 and 2014, respectively, and exclude the 9,000,000 shares loaned under the share lending arrangement.

Commitments_and_contingencies

Commitments and contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and contingencies	12. Commitments and contingencies
	Guarantees and Indemnifications — In the ordinary course of its business, the Company makes certain indemnities, commitments and guarantees under which it may be required to make payments in relation to certain transactions. The Company, as permitted under Delaware law and in accordance with its Bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. The Company has not recorded any liability for these indemnities in the accompanying condensed consolidated balance sheets. However, the Company accrues for losses for any known contingent liability, including those that may arise from indemnification provisions, when future payment is probable and the amount can be reasonably estimated.
	Litigation — The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. As of the date hereof, the Company believes that the final disposition of such matters will not have a material adverse effect on the financial position, results of operations or cash flows of the Company. The Company maintains liability insurance coverage to protect the Company’s assets from losses arising out of or involving activities associated with ongoing and normal business operations. In accordance with ASC 450 Contingencies, the Company would record a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.
	Contingencies — In connection with the Facility Agreement, on July 1, 2013 the Company also entered into a Milestone Rights Purchase Agreement (the “Milestone Agreement”) with Deerfield Private Design Fund and Horizon Santé FLML SÁRL (collectively, the “Milestone Purchasers”), pursuant to which the Company sold the Milestone Purchasers the Milestone Rights to receive payments up to $90.0 million upon the occurrence of specified strategic and sales milestones, including the first commercial sale of an AFREZZA product in the United States and the achievement of specified net sales figures (see Note 14 – Facility Agreement).
	Commitments — On July 31, 2014, the Company entered into the Insulin Supply Agreement, (the “Insulin Supply Agreement”), with Amphastar France Pharmaceuticals S.A.S. (“Amphastar”), pursuant to which the Company agreed to purchase certain annual minimum quantities of insulin for an aggregate total purchase price of approximately €120.1 million for calendar years 2015 through 2019.

Income_taxes

Income taxes	3 Months Ended
	Mar. 31, 2015
Income taxes	13. Income taxes
	As required by ASC 740 Income Taxes (“ASC 740”), management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and concluded, in accordance with the applicable accounting standards, that net deferred tax assets should be fully reserved.
	ASC 740-10-25 Income Taxes Recognition clarifies the accounting and disclosure for uncertainty in tax positions, as defined. This guidance seeks to reduce the diversity in practice associated with certain aspects of the recognition and measurement related to accounting for income taxes. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to this guidance. Tax years since 1993 remain subject to examination by the major tax jurisdictions in which the Company is subject to tax.

Facility_Agreement

Facility Agreement	3 Months Ended
	Mar. 31, 2015
Facility Agreement	14. Facility Agreement
	As of March 31, 2015, there were $60.0 million principal amount of 2019 notes and $20.0 million principal amount of Tranche B notes outstanding. The 2019 notes accrue interest at annual rate of 9.75% and the Tranche B notes accrue interest at an annual rate of 8.75%. The Facility Agreement principal repayment schedule is comprised of annual payments beginning on July 1, 2016 and ending December 9, 2019. The repayment dates correspond to the dates on which the 2019 notes or Tranche B notes, as applicable, were issued.
	In conjunction with the Facility Agreement, the Company entered into a Milestone Rights Agreement with Deerfield which requires the Company to make contingent payments to Deerfield, totaling up to $90.0 million, upon the Company achieving specified commercialization milestones.
	The Milestone Rights were initially recorded as a short-term liability equal to $3.2 million included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheet and a long-term liability equal to $13.1 million included in other liabilities. During the three months ended March 31, 2015, the second milestone triggering event was achieved following the Company’s product launch on February 3, 2015, which resulted in a $5.8 million incremental charge to interest expense due to the increase in carrying value of the liability to the required $10.0 million payment made in February of 2015. As of March 31, 2015, the Company determined that it was probable that the first commercial sales related milestone would be achieved within the next twelve months. As such, the company reclassified the corresponding $1.6 million long term liability to short term. As of March 31, 2015, the short-term portion of the liability had a balance of $1.6 million and the long-term portion of the liability had a balance of $7.3 million.
	Accretion of debt issuance cost and debt discount in connection with the Facility financing agreement during the three months ended March 31, 2015 and 2014 are as follows (in thousands):
		Three months ended		Three months ended
		March 31, 2015		31-Mar-14
	Accretion expense- debt issuance cost	$	9	$	282
	Accretion expense- debt discount	$	364	$	6,367
	The Facility Agreement contains a financial covenant that requires the Company’s cash and cash equivalents, which include available borrowings under the Loan Arrangement, on the last day of each fiscal quarter to not be less than $25.0 million. If the Company fails to satisfy this financial covenant, or another event of default occurs under the Facility Agreement, Deerfield may declare all or any portion of the 2019 notes and/or Tranche B notes to be immediately due and payable.

Description_of_business_and_ba1

Description of business and basis of presentation (Policies)	3 Months Ended
	Mar. 31, 2015
Business	Business — MannKind is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. Our only approved product, AFREZZA (insulin human [rDNA origin]) inhalation powder, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration (the “FDA”) on June 27, 2014 to improve glycemic control in adult patients with diabetes. In August 2014, we entered into a license and collaboration agreement (the “Sanofi License Agreement”) with Sanofi-Aventis Deutschland GmbH (which subsequently assigned its rights and obligations under the agreement to Sanofi-Aventis U.S. LLC (“Sanofi”)), pursuant to which Sanofi conducts all sales and marketing activities related to AFREZZA (see Note 7 – Collaboration arrangement). AFREZZA became available by prescription in United States retail pharmacies in February 2015.
Basis of Presentation	Basis of Presentation — The Company’s primary activities since incorporation have been establishing its facilities, recruiting personnel, conducting research and development, business development, business and financial planning, and raising capital. It is costly to develop therapeutic products and conduct associated clinical studies. As of March 31, 2015, the Company had an accumulated deficit of $2.5 billion and a stockholders’ deficit of $97.0 million. Historically the Company has reported negative cash flow from operations other than for the nine months ended September 30, 2014 and for the three months ended March 31, 2015, as a result of receipt of the upfront payment and milestone payments under the Sanofi License Agreement.
	At March 31, 2015, the Company’s capital resources consisted of cash and cash equivalents of $120.8 million. The Company expects to continue to incur significant expenditures to support commercial manufacturing of AFREZZA and the development of other product candidates. In addition, the Company had $232.5 million principal amount of outstanding debt as of March 31, 2015, including $100.0 million principal amount of outstanding 5.75% Senior Convertible Notes due 2015 (the “2015 notes”), which have a maturity date of August 15, 2015. See Note 5 – Related-party arrangements, Note 6 – Senior convertible notes, Note 7 – Collaboration arrangement—Sanofi Loan Facility, and Note 14 – Facility Agreement. In addition, the Company’s facility agreement (the “Facility Agreement”) with Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, “Deerfield”) (see Note 14 – Facility Agreement) contains a financial covenant that requires the Company’s cash and cash equivalents, which include available borrowings under the Company’s loan arrangement (the “Loan Arrangement”) with The Mann Group LLC (“The Mann Group”), on the last day of each fiscal quarter to not be less than $25.0 million. Should the holders of the notes not elect to convert such notes into the Company’s common stock prior to their due date, the Company intends to refinance the 2015 notes or raise additional funds to settle the 2015 notes. The Company cannot be certain that it will achieve its projected cashflows or be able to refinance the 2015 notes, which raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.
	On August 11, 2014, the Company executed a license and collaboration agreement (the “Sanofi License Agreement”) and a supply agreement (the “Sanofi Supply Agreement”) with Sanofi-Aventis Deutschland GmbH (which subsequently assigned its rights and obligations under the agreement to Sanofi-Aventis U.S. LLC (“Sanofi”)), pursuant to which Sanofi is responsible for global commercial, regulatory and development activities for AFREZZA. The Sanofi License Agreement became effective on September 23, 2014. The Company manufactures AFREZZA at its manufacturing facility in Danbury, Connecticut to supply Sanofi’s demand for the product. In addition, the Company and Sanofi are planning to collaborate to expand manufacturing capacity to meet global demand as necessary.
	Under the Sanofi License Agreement, Sanofi paid us an up-front cash payment of $150.0 million in the third quarter of 2014, and $50.0 million in milestone payments in the first quarter of 2015. The foregoing milestone payments were earned as of December 31, 2014. We are also eligible to receive up to $725.0 million in additional milestone payments under the Sanofi License Agreement if certain development, regulatory and sales milestones are achieved Worldwide profits and losses, which are determined based on the difference between the net sales of AFREZZA and the costs and expenses incurred by us and Sanofi that are specifically attributable or related to the development, regulatory filings, manufacturing, or commercialization of AFREZZA, will be shared 65% by Sanofi and 35% by us. In connection with the Sanofi License Agreement, an affiliate of Sanofi provided us with a secured loan facility (the “Sanofi Loan Facility”) of up to $175.0 million to fund our share of net losses under the Sanofi License Agreement.
	Additional funding sources that are, or in certain circumstances may be available to the Company, include approximately $30.1 million principal amount of available borrowings under its Loan Arrangement (see Note 5 – Related-party arrangements), potential proceeds from the exercise of warrants issued in its February 2012 public offering of approximately $14.9 million, and the Company’s at-the-market issuance sales agreements which allow the Company to sell up to $50.0 million in common stock provided no sales may be made except pursuant to an effective registration statement. The registration statement under which the shares that may be sold pursuant to the at-the-market issuance sales agreements are registered will expire in August 2015. The Company cannot provide assurances that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company may need to raise additional capital, whether through a sale of equity or debt securities, a strategic business collaboration with a pharmaceutical company, the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to continue the development and commercialization of AFREZZA and other product candidates and to support its other ongoing activities. However, the Company cannot provide assurances that such additional capital will be available on acceptable terms or at all.
Fair Value of Financial Instruments	Fair Value of Financial Instruments — The carrying amounts reported in the accompanying financial statements for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their relatively short maturities. The fair value of the cash equivalents, note payable to related party, senior convertible notes, and the Facility Agreement are discussed in Note 9 – Fair Value of Financial Instruments.
Deferred product costs from collaboration	Deferred product costs from collaboration — Deferred product costs represent the costs of product manufactured and shipped to Sanofi, not to exceed the amount of deferred product sales related to the collaboration, for which recognition of revenue has been deferred. Given that the costs of inventory delivered to a customer, but for which revenue may not yet be recognized, meet both the definition and characteristics of an “Asset” and the Company believes that it is probable that the amount of future revenue will exceed the amount of deferred costs (i.e., the asset would be realizable through the recognition of probable future income), the Company has elected to account for the deferred costs related to the product sold to Sanofi as an asset and carry forward to future periods until the related revenue is recognized.
Recently Issued Accounting Standards	Recently Issued Accounting Standards — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date.
	In May 2014, a new standard was issued related to revenue recognition, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The guidance requires a company to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration it expects to be entitled to receive in exchange for those goods or services. The standard is effective beginning the first quarter of the Company’s 2018 fiscal year (with early adoption not permitted) and may be adopted either by restating all years presented in the Company’s financial statements or by recording the impact of adoption as an adjustment to retained earnings at the beginning of fiscal 2018 The Company is assessing the potential impact of the new standard on its consolidated statements of financial position and results of operations and comprehensive income (loss) and has not yet selected a transition method.
	In August 2014, the FASB issued ASU 2014-15, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is “substantial doubt about the entity’s ability to continue as a going concern.” The ASU is effective for annual periods ending after December 15, 2016, and interim periods thereafter; early adoption is permitted. The Company is evaluating the impact the adoption of ASU 2014-15 will have on its consolidated financial statements.
	In April 2015, the FASB issued ASU 2015 03, “Simplifying the Presentation of Debt Issuance Costs.” The guidance requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt, consistent with the presentation of a debt discount. The guidance is effective for annual reporting periods beginning after December 15, 2015 and interim periods thereafter. Early adoption is permitted. The Company does not believe the adoption of the new standard will have a material impact on its consolidated financial statements and disclosures.

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Components of Inventories	Inventories consist of the following (in thousands):
		March 31,		December 31,
		2015		2014
	Raw materials	$	10,075	$	4,856
	Work-in-process		5,550		4,719
	Finished goods		1,164		95
	Total inventories	$	16,789	$	9,670

Property_and_equipment_Tables

Property and equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Property and Equipment	Property and equipment — net consist of the following (dollar amounts in thousands):
		Estimated		March 31,			December 31,
		Useful		2015			2014
		Life
		(Years)
	Land		—	$	5,273		$	5,273
	Buildings		39-40		54,948			54,948
	Building improvements		May-40		114,131			114,131
	Machinery and equipment		15-Mar		82,120			80,919
	Furniture, fixtures and office equipment		10-May		5,015			5,015
	Computer equipment and software		3		10,499			10,465
	Leasehold improvements		4		17			17
	Construction in progress				41,997			39,580
					314,000			310,348
	Less accumulated depreciation and amortization				(120,546	)		(118,221	)
	Property and equipment — net			$	193,454		$	192,127

Accrued_expenses_and_other_cur1

Accrued expenses and other current liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following (in thousands):
		March 31,		December 31,
		2015		2014
	Salary and related expenses	$	7,386	$	14,928
	Accrued interest		1,022		2,396
	Construction in progress		579		1,343
	Other		3,394		7,539
	Accrued expenses and other current liabilities	$	12,381	$	26,206

Senior_convertible_notes_Table

Senior convertible notes (Tables)	3 Months Ended
	Mar. 31, 2015
Summary of Senior Convertible Notes	Senior convertible notes consist of the following (in thousands):
		March 31,			December 31,
		2015			2014
	2015 notes
	Principal amount	$	100,000		$	100,000
	Unaccreted debt issuance expense		(407	)		(645	)
	Net carrying amount	$	99,593		$	99,355

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2015
Summary of Carrying Values and Estimated Fair Values of Notes and Facility Financing Obligation	The following is a summary of the carrying values and estimated fair values of the 2015 notes and the facility financing obligation (i.e., the 2019 notes and Tranche B notes) (in millions):
		March 31, 2015				December 31, 2014
		Carrying		Estimated		Carrying		Estimated
		value		fair value		value		fair value
	2015 notes	$	99.6	$	102.1	$	99.4	$	102.9
	Facility financing obligation	$	73.4	$	76.1	$	73	$	75.1

Facility_Agreement_Tables

Facility Agreement (Tables)	3 Months Ended
	Mar. 31, 2015
Accretion of Debt Issuance Cost and Debt Discount	Accretion of debt issuance cost and debt discount in connection with the Facility financing agreement during the three months ended March 31, 2015 and 2014 are as follows (in thousands):
		Three months ended		Three months ended
		March 31, 2015		31-Mar-14
	Accretion expense- debt issuance cost	$	9	$	282
	Accretion expense- debt discount	$	364	$	6,367

Recovered_Sheet1

Description of Business and Basis of Presentation - Additional Information (Detail) (USD $)	3 Months Ended	0 Months Ended	3 Months Ended
	Mar. 31, 2015	Aug. 11, 2014	Sep. 30, 2014	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 23, 2014
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Accumulated deficit	($2,525,447,000)			($2,494,784,000)
Stockholders' deficit	-97,031,000			-73,770,000
Cash and cash equivalents	120,844,000			120,841,000	35,759,000	70,790,000
Principal amount of outstanding debt	232,500,000
Amount available for future borrowings	30,100,000
Potential proceeds from the exercise of warrants from February 2012 public offering	14,900,000
Maximum | ATM Agreements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Offering price of common stock under agreement	50,000,000
Senior convertible notes due August 15, 2015
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Principal amount of outstanding debt	100,000,000
Senior notes, effective interest rate	5.75%
Maturity date	15-Aug-15
Deerfield | Senior convertible notes due December 31, 2019
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Senior notes, effective interest rate	9.75%
Deerfield | Senior convertible notes due December 31, 2019 | Less portion of commitment asset
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Senior notes, effective interest rate	8.75%
Deerfield | Senior convertible notes due December 31, 2019 | Minimum | Facility Agreement | Less portion of commitment asset
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Available amount of credit facility under covenant restrictions	25,000,000
License and Collaboration Agreement with Sanofi
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Senior notes, effective interest rate							8.50%
Up-front fee			150,000,000
Potential milestone payment	725,000,000	725,000,000
Profits and losses sharing percentage	35.00%	35.00%
Maximum secured loan facility							175,000,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Profits and losses sharing percentage	65.00%	65.00%
Maximum secured loan facility	175,000,000
License and Collaboration Agreement with Sanofi | Manufacturing Milestone Events
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Milestone payments earned	$50,000,000

Components_of_Inventories_Deta

Components of Inventories (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory [Line Items]
Raw materials	$10,075	$4,856
Work-in-process	5,550	4,719
Finished goods	1,164	95
Total inventories	$16,789	$9,670

Property_and_Equipment_Detail

Property and Equipment (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment - gross	$314,000	$310,348
Less accumulated depreciation and amortization	-120,546	-118,221
Property and equipment - net	193,454	192,127
Land
Property, Plant and Equipment [Line Items]
Property and equipment - gross	5,273	5,273
Buildings
Property, Plant and Equipment [Line Items]
Property and equipment - gross	54,948	54,948
Buildings | Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	39 years
Buildings | Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	40 years
Building Improvements
Property, Plant and Equipment [Line Items]
Property and equipment - gross	114,131	114,131
Building Improvements | Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	5 years
Building Improvements | Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	40 years
Machinery and Equipment
Property, Plant and Equipment [Line Items]
Property and equipment - gross	82,120	80,919
Machinery and Equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	3 years
Machinery and Equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	15 years
Furniture, fixtures and office equipment
Property, Plant and Equipment [Line Items]
Property and equipment - gross	5,015	5,015
Furniture, fixtures and office equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	5 years
Furniture, fixtures and office equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	10 years
Computer Equipment and Software
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	3 years
Property and equipment - gross	10,499	10,465
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Estimated Useful Life (Years)	4 years
Property and equipment - gross	17	17
Construction in Progress
Property, Plant and Equipment [Line Items]
Property and equipment - gross	$41,997	$39,580

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Depreciation and Other Amortization Expenses [Line Items]
Amortization period of lease hold improvements	4 years
Depreciation and amortization expense	$2.30	$2.50

Recovered_Sheet2

Accrued Expenses and Other Current Liabilities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Accrued Expenses and Other Current Liabilities [Line Items]
Salary and related expenses	$7,386	$14,928
Accrued interest	1,022	2,396
Construction in progress	579	1,343
Other	3,394	7,539
Accrued expenses and other current liabilities	$12,381	$26,206

RelatedParty_Arrangements_Addi

Related-Party Arrangements - Additional Information (Detail) (USD $)	1 Months Ended		3 Months Ended
	Oct. 31, 2013	Oct. 31, 2007	Mar. 31, 2015
Related Party Transaction [Line Items]
Amount available for future borrowings			$30,100,000
Additional borrowings			0
Principal stockholder
Related Party Transaction [Line Items]
Loan agreement with related party	370,000,000	350,000,000
Principal stockholder | Loan Arrangement
Related Party Transaction [Line Items]
Principal amount outstanding under credit facility			49,500,000
Amount available for future borrowings			30,100,000
Fixed borrowing rate			5.84%
Interest payable			4,200,000
Related party transaction prepayment period			90 days
Aggregate principal amount cancelled			105,000,000
Principal stockholder | Loan Arrangement | Maximum
Related Party Transaction [Line Items]
Amount prepaid for cancellation of indebtedness			$200,000,000
Principal stockholder | Loan Arrangement | Minimum
Related Party Transaction [Line Items]
Number of months advances outstanding			12 months
Principal stockholder | Amended Agreement
Related Party Transaction [Line Items]
Promissory note maturity date	5-Jan-20
Related Party Debt | Letter Agreement
Related Party Transaction [Line Items]
Description of variable rate interest			The interest rate will increase to the one-year LIBOR calculated on the date of the initial advance or in effect on the date of default, whichever is greater, plus 5% per annum.
Related Party Debt | Letter Agreement | LIBOR
Related Party Transaction [Line Items]
Interest rate (LIBOR)			5.00%

Summary_of_Senior_Convertible_

Summary of Senior Convertible Notes (Detail) (Senior convertible notes due August 15, 2015, USD $)	Mar. 31, 2015	Dec. 31, 2014	Aug. 18, 2010
In Thousands, unless otherwise specified
Senior convertible notes due August 15, 2015
Debt Instrument [Line Items]
Principal amount	$100,000	$100,000	$100,000
Unaccreted debt issuance expense	-407	-645
Net carrying amount	$99,593	$99,355

Senior_Convertible_Notes_Addit

Senior Convertible Notes - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Aug. 18, 2010	Dec. 31, 2014
			D
Debt Instrument [Line Items]
Accretion of debt issuance costs	$238,000	$223,000
Senior convertible notes due August 15, 2015
Debt Instrument [Line Items]
Principal amount	100,000,000		100,000,000	100,000,000
Accrued interest payable	1,000,000			2,400,000
No of convertible shares			147.0859
Principal amount per share			$1,000
Conversion price of shares			$6.80
Percentage of repurchase price			100.00%
Percentage of conversion price equaling stock price			150.00%
Number of trading days			20
Consecutive trading days			30 days
Debt Issuance Cost			4,200,000
Senior notes, effective interest rate	5.75%
Senior convertible notes due December 31, 2019 | Deerfield
Debt Instrument [Line Items]
Principal amount	60,000,000
Senior notes, effective interest rate	9.75%
Senior convertible notes due December 31, 2019 | Deerfield | Less portion of commitment asset
Debt Instrument [Line Items]
Principal amount	$20,000,000
Senior notes, effective interest rate	8.75%

Collaborative_Arrangement_Addi

Collaborative Arrangement - Additional Information (Detail) (USD $)	0 Months Ended		3 Months Ended		1 Months Ended
	Sep. 23, 2014	Aug. 11, 2014	Mar. 31, 2015	Sep. 30, 2014	11-May-15
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred cost			$6,251,000
License and Collaboration Agreement with Sanofi
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Up-front fee				150,000,000
Potential milestone payment		725,000,000	725,000,000
Profits and losses sharing percentage		35.00%	35.00%
Maximum secured loan facility	175,000,000
Senior notes, effective interest rate	8.50%
Prepayment of loan percentage of net cash proceeds sale	100.00%
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Profits and losses sharing percentage		65.00%	65.00%
Deferred revenue from collaboration product shipments			150,000,000
Milestone receivable			50,000,000
Deferred cost			6,300,000
Loss sharing amount reclassified to other long-term liabilities			12,400,000
Maximum secured loan facility			175,000,000
Secured loan facility, amount borrowed			3,000,000
Secured loan facility, amount owed					15,500,000
Paid-in-kind interest					100,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Subsequent Event
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Secured loan facility, amount borrowed					12,400,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | AFREZZA product sales
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue from collaboration product shipments			7,100,000
License and Collaboration Agreement with Sanofi | Manufacturing Milestone Events
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments earned			50,000,000
Number of milestones achieved			2
License and Collaboration Agreement with Sanofi | Development Milestone Event
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payment		25,000,000
License and Collaboration Agreement with Sanofi | Regulatory Approvals
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payment		50,000,000
License and Collaboration Agreement with Sanofi | Product Sales Milestones
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payment		$650,000,000

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Sep. 23, 2014	Jul. 01, 2013
Fair Value of Financial Instruments [Line Items]
Cash and cash equivalents	$120,844,000	$35,759,000	$120,841,000	$70,790,000
Cash equivalents, money market funds	120,500,000		118,500,000
Transfers of assets between fair value measurement	0	0
Transfers of liabilities between fair value measurement	0	0
License and Collaboration Agreement with Sanofi
Fair Value of Financial Instruments [Line Items]
Maximum secured loan facility					175,000,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH
Fair Value of Financial Instruments [Line Items]
Maximum secured loan facility	175,000,000
Secured loan facility, amount borrowed	3,000,000
Milestone Rights Liability | Deerfield | Maximum
Fair Value of Financial Instruments [Line Items]
Contingent liability for milestone payments						90,000,000
Fair Value, Inputs, Level 3 | Milestone Rights Liability
Fair Value of Financial Instruments [Line Items]
Fair value of Milestone Rights	$47,600,000
Fair Value, Inputs, Level 3 | Income Approach Valuation Technique | Milestone Rights Liability
Fair Value of Financial Instruments [Line Items]
Market discount rate	15.00%
Fair Value, Inputs, Level 3 | Senior convertible notes due December 31, 2019 | Income Approach Valuation Technique
Fair Value of Financial Instruments [Line Items]
Market discount rate	12.00%
Fair Value, Inputs, Level 3 | Senior convertible notes due December 31, 2019 | Income Approach Valuation Technique | Less portion of commitment asset
Fair Value of Financial Instruments [Line Items]
Market discount rate	11.00%

Summary_of_Carrying_Values_and

Summary of Carrying Values and Estimated Fair Values of Notes and Facility Financing Obligation (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Senior convertible notes due August 15, 2015
Convertible Debt [Line Items]
Carrying value	$99,593,000	$99,355,000
Estimated fair value	102,100,000	102,900,000
Facility financing obligation
Convertible Debt [Line Items]
Carrying value	73,400,000	73,000,000
Estimated fair value	$76,100,000	$75,100,000

Common_and_Preferred_Stock_Add

Common and Preferred Stock - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Aug. 18, 2010
Class of Stock [Line Items]
Common stock loaned under share lending agreement, shares	9,000,000	9,000,000
Nominal lending fee	$0.01
Senior convertible notes due August 15, 2015
Class of Stock [Line Items]
Principal amount	$100,000	100,000	$100,000

Accounting_for_Stock_Based_Com

Accounting for Stock- Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$2,000,000	$5,200,000
Number of restricted stock units issued	36,300
Number of stock options issued	73,600
Weighted average vesting period for unrecognized compensation cost	2 years 7 months 6 days
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based payment award , vesting period	4 years
Fair value of the stock options granted , value	382,720
Weighted average grant date fair value of the stock options granted	$5.20
Unrecognized compensation cost related to non vested stock options	9,000,000
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of Restricted stock options granted , value	262,086
Weighted average grant date fair value of the stock options granted	$7.22
Unrecognized compensation cost related to non vested stock options	10,000,000
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non vested stock options	0
Performance Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non vested stock options	$0

Net_Loss_per_Common_Share_Addi

Net Loss per Common Share - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Net Income Loss Per Common Share [Line Items]
Companies common stock share outstanding	9,000,000
Antidilutive securities	45,171,595	67,791,150
Shares loaned under the share lending arrangement	9,000,000	9,000,000

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail)	0 Months Ended
In Millions, unless otherwise specified	Jul. 31, 2014	Jul. 01, 2013
	EUR (€)	Deerfield
		Milestone Rights Liability
		Maximum
		USD ($)
Commitments and Contingencies [Line Items]
Contingent liability for milestone payments		$90
Purchase commitment amount under Insulin Supply Agreement	€ 120.10

Facility_Agreement_Additional_

Facility Agreement - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Jul. 01, 2013
Debt Instrument [Line Items]
Short term liability	$73,368,000		$72,995,000
Interest expense on notes	9,622,000	4,042,000
Deerfield
Debt Instrument [Line Items]
Principal repayment schedule, start date	1-Jul-16
Principal repayment schedule, end date	9-Dec-19
Deerfield | Milestone Rights Liability | Maximum
Debt Instrument [Line Items]
Contingent liability for milestone payments				90,000,000
Deerfield | Senior convertible notes due December 31, 2019
Debt Instrument [Line Items]
Debt facility principal amount	60,000,000
Senior notes, effective interest rate	9.75%
Deerfield | Senior convertible notes due December 31, 2019 | Milestone Rights Liability
Debt Instrument [Line Items]
Short term liability	1,600,000			3,200,000
Long term liability	7,300,000			13,100,000
Interest expense on notes	5,800,000
Required payment pursuant to the terms of the Milestone Agreement	10,000,000
Deerfield | Senior convertible notes due December 31, 2019 | Less portion of commitment asset
Debt Instrument [Line Items]
Debt facility principal amount	20,000,000
Senior notes, effective interest rate	8.75%
Deerfield | Senior convertible notes due December 31, 2019 | Less portion of commitment asset | Minimum | Facility Agreement
Debt Instrument [Line Items]
Available amount of credit facility under covenant restrictions	$25,000,000

Accretion_of_Debt_Issuance_Cos

Accretion of Debt Issuance Cost and Debt Discount in Connection with Deerfield Financing (Detail) (Deerfield, USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Deerfield
Debt Instrument [Line Items]
Accretion expense- debt issuance cost	$9	$282
Accretion expense- debt discount	$364	$6,367